Detection of symmetrical dimethylarginine
The disclosure generally relates to the detection of symmetrical dimethylarginine (SDMA). More particularly, the disclosure relates to the detection of SDMA using a solid phase. The disclosure provides devices, reagents, kits and methods for detecting symmetrical dimethyl arginine (SDMA) in sample, such as a biological sample from an animal. The method includes detecting the presence or amount of SDMA in the sample by using an immunoassay format, such as a competitive immunoassay. The assay includes the use of antibodies to SDMA that are specific for SDMA and that have less affinity for other arginine derivatives.
1. A device for determining symmetrical dimethyl arginine (SDMA) in a sample, comprising a solid matrix comprising a particle non-diffusively bound thereto, wherein the particle comprises a capture reagent comprising (a) N-methylarginine (MMA) covalently attached to a protein that is attached to the particle or (b) N-methylarginine (MMA) covalently attached to the particle.
2. The device of claim 1 , wherein the protein is covalently attached to the particle.
3. The device of claim 1 , wherein the protein is non-covalently attached to the particle.
4. The device of claim 1 , wherein the protein is at least one protein selected from the group consisting of Bovine Serum Albumin (BSA), ovalbumin, Keyhole Limpet Hemocyanin (KLH), and Glucose-6-Phosphate Dehydrogenase (G6PDH).
5. The device of claim 4 , wherein the protein is G6PDH.
6. The device of claim 5 , wherein the G6PDH is derived from a eukaryote, a prokaryote, a yeast or recombinant expression.
7. The device of claim 1 , wherein the solid matrix is a porous matrix.
8. The device of claim 7 , wherein the solid matrix is arranged in a cartridge or housing.
9. A method of determining symmetrical dimethyl arginine (SDMA) in a sample, comprising
(a) forming a mixture comprising the sample and a labeled conjugate comprising an anti-SDMA antibody conjugated to a label;
(b) contacting the mixture with the device of claim 1 ;
(c) washing the solid matrix to remove conjugate that is not bound to the solid matrix; and
(d) measuring the amount of the label associated with the solid matrix to determine the presence or amount of SDMA in the sample.
10. A capture reagent comprising N-methylarginine (MMA) attached to a particle.
11. The capture reagent of claim 10 , wherein the MMA is bound to the particle through a linker.
12. The capture reagent of claim 11 , wherein the linker comprises the following structure:
13. The capture reagent of claim 12 , comprising:
14. The capture reagent of claim 10 , wherein the MMA is covalently attached to a protein that is attached to a particle.
15. The capture reagent of claim 14 , wherein the protein is covalently attached to the particle.
16. The capture reagent of claim 14 , wherein the protein is non-covalently attached to the particle.
17. The capture reagent of claim 14 , wherein the protein is at least one protein selected from the group consisting of Bovine Serum Albumin (BSA), ovalbumin, Keyhole Limpet Hemocyanin (KLH), and Glucose-6-Phosphate Dehydrogenase (G6PDH).
18. A method of determining symmetrical dimethyl arginine (SDMA) in a sample, comprising
(a) forming a mixture comprising the sample and an anti-SDMA antibody;
b) contacting the mixture with a solid matrix comprising the capture reagent of claim 10 ;
(c) washing the solid matrix to remove the anti-SDMA antibody that is not bound to the solid matrix; and
(d) measuring the amount of the anti-SDMA antibody associated with the solid matrix to determine the presence or amount of SDMA in the sample.
19. The method of claim 18 , wherein the anti-SDMA antibody is labeled.
20. A solid phase comprising N-methylarginine (MMA) covalently attached to G6PDH, wherein the G6PDH is non-covalently attached to a particle.
21. The solid phase of claim 20 , further comprising a porous matrix.
22. The solid phase of claim 21 , wherein the porous matrix is mounted in a housing.